Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are associated with a lower risk of all-cause hospitalization (HR 0.85) compared to dipeptidyl peptidase-4 inhibitors (DPP4i).

• During a median follow-up of 16 months, SGLT2i and glucagon-like peptide-1 receptor agonists (GLP-1RA) were linked to reduced rates of all-cause hospitalization compared to DPP4i.
• SGLT2i and GLP-1RA were associated with lower risk of cardiovascular disease hospitalization compared to DPP4i.
• The risks of all-cause and cardiovascular hospitalization were similar between SGLT2i and GLP-1RA.
• SGLT2i showed a notably lower risk of myocardial infarction and heart failure hospitalization compared to DPP4i.
• The risk of non-cardiovascular disease hospitalization did not differ among the treatment groups.

AI simplified